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Summary.-Results after an average follow-up of 3 years are presented on 485
patients in the 3rd MRC therapeutic trial in myelomatosis. The 353 non-azotaemic
patients (199 now dead) were randomized between i.v. cyclophosphamide (CY) and
oral melphalan with prednisone (M & P).Thosetreated with M & P fared slightly, but
non-significantly, better. The 132 azotaemic patients (111 now dead) were randomized
between i.v. CY and a 4-drug regimen, and both groups fared equally badly. Finally,
after one year pf the allocated treatment, 297 survivors (126 now dead) were random-
ized either to stop all treatment until evidence of relapse was obtained, or to continue
treatment with azathioprine and vincristine, interrupted every 3 months for a course
of the first-allocated treatment. The overall results suggested that maintenance
therapy was beneficial, though the results were not statistically significant. Most of
the difference wasfound among thefew patients with unfavourableprognosticfeatures
who survived one year and were eligible for this randomization. In this, as in the two
previous MRC trials, no striking differences have emerged between the therapeutic
effects of different schedules of melphalan and/or CY. Consequently, a regimen of
intermittent oral melphalan (with or without prednisone) seems satisfactory, because
it is among the least toxic and most convenient. The 4th myeloma trial, now begin-
ning, seeks to discover whether the addition ofvincristine to the regimen can improve
these results.
IN THE 1st MRC therapeutic trial in
myelomatosis (MRC, 1971; 1973) the
effects of melphalan and cyclophosph-
amide (CY) were compared in 258 patients
entered in 1964-68. Both drugs were given
orally on a long-term basis at low daily
dosage, and the patients allocated con-
tinuous CY fared slightly better, though
the difference was small and not statistic-
ally significant.
In the 2nd trial (MRC, 1980) 3 oral
treatment schedules were compared in 372
patients entered from 1968 to 1975. One
of these treatments, continuous CY, was
carried over from the 1st trial, whilst the
other 2 both involved 7-day courses of
melphalan given every 6-8 weeks, one
with and the other without prednisone.
Comparing these 3 groups of patients, no
differences in survival were eventually
apparent, despite moderate differences in
preliminary analyses.MRC WORKING PARTY ON LEUKAEMIA IN ADULTS
(1)
(2)
(3)
TABLE I.-Treatment protocols
Initial treatment
Melphalan 10 mg/day for 7 days, oral 3 *
Prednisone 40 mg/day for 7 days, oral every 3 weeks
Cyclophosphamide 600 mg/M2 i.v. every 3 weeks
Intensive (4-drug)
Cyclophosphamide 250 mg/M2 daily for 3 days, oral
Melphalan 6 mg/M2 daily for 3 days, oral e
Prednisone 40 g/m2 daily for 3 days, oral ,
CCNU 50 mg/M2 on Day 4 only
every 4
weeks*
Alaintenance
13-week cycle repeated in(lefinitely*:
Induction therapy (1, 2 or 3 as previously allocated) oii Week 0
Vincristine 1 mg i.v. Weeks 4 and 8
Azathioprine 60 mg/M2 daily from Week 4 for 6 weeks:
Induction VCR VCR
course
Azathioprine daily
return to WVeek 0
IIIIIIII Ill l Il IlIIl
0 1 2 3 4 5 6 7 8 9 10 11 12 13
* In the presence of neutropenia, thrombocytopenia or azotaemia, scheduled treatment was reduced or
delayed.
In both previous trials overall survival
compared reasonably well with published
series from other countries, but the sur-
vival ofthose patients who presented with
a high blood urea concentration (BUC)
was very poor. Therefore, in the 3rd trial,
the subject of this paper, patients were
stratified at presentation into an "azot-
aemic" group, with a BUC which (after a
variable amount ofrehydration) was > 10
mM (60 mg/100 ml) and a "non-azotaemic"
remainder. In the non-azotaemic group
melphalan andprednisone were again com-
pared with CY, the latter administered
i.v. at high dosage at 21-day intervals,
whilst in the azotaemic stratum CY was
compared with a 4-drug schedule com-
prising CY, melphalan, prednisone and
CCNU. A third question, whether one year
of cytotoxic treatment was sufficient, or
ifmoreprolongedtreatment was beneficial,
was also asked.
Details of the cytotoxic schedules are
given in Table I, and a summary of the
present trial design is given in Fig. 1.
In the non-azotaemic population, the
use ofi.v, CY had the advantages of lesser
myelotoxicity and the certainty that
patients actually received the drug pre-
scribed; on the other hand previous ex-
perience had shown that intermittent oral
M & P had practical advantages in ease of
administration, and somewhat fewer side-
effects than were anticipated with CY
(e.g. vomiting, alopecia or haematuria).
The 4-drug schedule for azotaemic
patients was aimed at a rapid reduction in
serum and urinary paraprotein levels, in
the hope that further deterioration of
renal function could be prevented, and
that sufficient renal function would re-
main. The standard method using CY and
melphalan often takes a few months to
achieve substantial paraprotein reduc-
tions, and Azam & Delamore (1974) had
previously tested the 4-drug regimen and
reported that it could sometimes produce
a rapid improvement in advanced myelo-
matosis.
Finally, for patients who had been
treated with cytotoxic agents for over a
year and whose myeloma seemed to be
static, it was not clear whether continued
cytotoxic attack would be beneficial or
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Treatment Allocation Initial Treatment
1 year
4-drug regimen |
FIG. 1.-Flow diagram of the trial design.
harmful. Salmon etat. (1975) hadsuggested
that as the myeloma regressed under
attack by alkylating agents the growth
fraction increased until a balance was
reached where further regression could
only be achieved by the use ofcycle-active
drugs. Consequently, after one year,
patients were randomly allocated to con-
tinue indefinite cytotoxic treatment, and
azathioprine and vincristine were added
to the alkylating agent initially used. 297
patients were entered into this part of the
study.
PATIENTS AND METHODS
Patients were eligible for entry ifthey were
under the age of 75, with newly diagnosed
myelomatosis, andwith no history ofsystemic
radiotherapy or of treatment with any cyto-
toxic agent for any condition (local radio-
therapy was permissible). The diagnosis of
myelomatosis had to be supported by at least
2 ofthe following:
(i) Plasma-cell infiltration in marrow smears
or sections.
(ii) Definite osteolytic lesions in skeletal
X-rays.
(iii) Monoclonal immunoglobulin in serum or
urine.
Entry into the trial was by telephone to the
Leukaemia Trials Office, London, for a ran-
dom treatment allocation, followed byposting
documentation of the basis for the diagnosis,
together with various clinical or biochemical
details. 508 patients were submitted for entry
but 23 of these were ineligible, unidentifiable
or not properly documented by post (Table
II). Of the remaining 485 patients, 132 (111
dead by 1 January 1980) entered the azot-
aemic group and were randomized between
CY and the 4-drug regimen, and 353 (199
TABLE II.-Patient distribution
Total entered
Exclusions
Misdiagnosis
Over 75 years ofage
Untraced
Incomplete records
Total exclusions
Patients analysed
BUC < 10 mM
BUC > 10 mM
508
5
7
4
7
23 (4-5%)
485 (95.5%)
353 (73%)
132 (27%)
dead by 1 January 1980) were in the non-
azotaemic stratum and were randomized
between CY and M & P.
Patients were eligible for the second
randomization ifthey had completed at least
one year of their allocated primary therapy,
and if the physician considered it reasonable
to randomize them between no further treat-
ment (unless specifically indicated) and cycle-
active maintenance. A total of 297 (126 dead
by 1 January 1980) were so randomized.
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Follow-up was by written enquiry each
January and July, supplemented by "flag-
ging" the patients' records at the NHS
central register at Southport, which provides
the dates of any deaths of untraced patients.
The statistical methods used are as recom-
mended by Peto et al. (1976, 1977). Life
tables are calculated by the actuarial method,
and logrank "expected" numbers of deaths
in various groups are calculated (under the
null hypothesis that the risk of death among
the actual survivors at any particular time is
unrelated to treatment). Ratios of observed
to expected numbers are referred to as
"relative death rates". All P values relate to
2-tailed tests based on logrank statistics.
RESULTS
This trial is in effect 3 largely inde-
pendent randomized subtrials, and each
will be discussed separately. First, how-
ever, our prognostic grouping must be
defined (for discussion, see accompanying
paper (MRC, 1980)).
(1) Good prognosis patients (22%) are
those who present with no (or mini-
mal) symptoms, andwithout evidence
ofanaemia (Rb > 100g/l)orazotaemia
(BUC (8mm).
(2) Intermediate prognosis patients (56%)
are those whose presenting features
do not qualify them for either the
good or poor prognosis groups.
(3) Poor prognosis patients (22%) are
those who present both with symp-
toms which restrict their activity, and
with either definite anaemia (Hb < 75
g/l) or raised (BUC > 10 mM) or both.
These prognostic groupings were de-
vised without reference to the differences
between treatments, and subdivide the
patients into groups with markedly differ-
ent life expectancy.
Sub-trial No. 1: First-line cytotoxic treat-
mentfor patients having BUC < 10 mM
Among the 353 patients randomized
between i.v. CY and oral M & P, there was
no material difference in the distribution
of any feature between the two treatment
groups (Table III). A small improvement
in survival is seen in the M & P arm, but
it is not statistically significant (P= 0.16).
However, in view of the lack of difference
in survival between continuous CY and
melphalan in the first two MRC trials, this
difference should be treated cautiously,
especially since the probability of a differ-
ence at least as big as this arising by
chance alone is about 1 in 6 (Table IV).
TABLE IV. Deaths in the non-azotaemic
stratum ofpatients in relation tofirst-line
treatment
Ob-
First-line No. of
treatment patients
CY(i.v.) 174
M & P (p.o.) 179
Total 353
served
No.
dead
(0)
105
94
199
Expected*
No. dead
(E)
95-14
103-86
199-00
Relative
death
rate
(O/E)
1-10
0-91
(x2= 1-96,
P=0-16)
* Expected number ofdeaths represents the extent
of exposure to risk of death for patients in this
group.
Since the patients receiving the M & P
combination have actually fared a little
better than the CY-treated patients, it is
safe to conclude that this approach is no
worse, and probably as good as or better
than CY alone. Moreover, since oral M & P
is better tolerated by the patients than i.v.
TABLE III.-Mean values atpresentation ofclinical and laboratoryfeatures in allpatients
randomized between melphalan/prednisone and cyclophosphamide. No difference is
significant at the 10% level
Age
(yrs)
M&P 62-6
CY 61-3
% Male
47-8
55-1
Post-
hydration
blood urea Hb IgM Platelets
(mM) (g/l) (g/l) (109/1)
5-8 105 0-25 243
6-2 105 0-26 245
Serum
calcium
(mM)
2-47
2-49
Serum
alkaline
phos-
phatase
(i.u.)
88-9
95-2
WBC
(109/1)
6-5
6-7
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(Y and is more convenient to administer,
it wouild appear to be the treatment of
choice. However, it is more myelosup-
pressive and consequently it is necessary
to reduce the size or the frequency of the
dose, or both, in some patients.
In a random sample of 21 good-prog-
nosis patients, a review of the clinical
notes revealed that 7/12 patients treated
with M & P had one or more platelet
counts below 50 x 109/1 during the first 6
monthsoftreatment, whereasthis occurrecl
in none of the 9 patients treated with CY.
In a sample of poor-prognosis patients
this event occurre(1 in 6/7 patients on
M & P, but in only 5/14 on CY. Further-
more, there were :3 early (leaths due to
thrombocytopenia in the poor-prognosis
group on M & P while none occurred in the
other subgroups of this sample. Initial
platelet counts were not predictive of a
later thrombocytopenia during treatment.
Thuts, some arnacemic patients cannot re-
ceive enouglh melphalan to control their
disease, and some of these tolerate i.v. CY
and respond well.
Adjustment (by r-etrospective stratifica-
tion) for various prognostic feattures,
neither strengthened nor weakened the
nett magnitude of the overall treatment
difference in Fig. 2 and Table I\-, and so
did not affect the jtudgement that chance
alone could well be responsible for that
difference when the patients were divided
into subgroups in variouis ways. Certain
subgrotups showed somewhat larger stur-
vival differences whiclh coul( also be due
to chance. However, the demonstrable
difference in the myelotoxicity of the two
regimens may well explain -why the low-
Fic C.> eatment comparisons for the nioIn-
azotaermic stratuim of patients (BUC < 10
mN). x2= 1-96, P=0-16. Number of
patients in ea-h grouip given in parentheses.
haemoglobin group did worse on M & P
and also, if myelotoxicity and myeloma
cell lethality are related, why the non-
anaemic remainder fared marginally better
oIn M & P. The size of the differences and
the weight of the ancillary evidence are
not a robust foundation for the future
selection of treatment, but they are better
than none at all.
In addition it should be pointed out that
anecdotal evidence, some derived from
patients within this trial, indicates that
there are cases who may respond to
melphalan and not to CY, and vice versa.
Such evidence was not looked for system-
atically in this trial, but it exposes certain
limitations of any overall analysis wlhich
seeks to compare two treatments. Such
analyses can indicate which type of treat-
ment it is advisable to try out first, but the
subsequient optimum treatment of the
TA13LE V. First-line treatmient in the non-azotaemic stratunt of patients: treatment dif-
ferences amony miales andfemales separately in the non-azotaemic stratum ofpatients
Al & P (p.o.)
N () E ()/E
87 48 56-4 (085
92 46 47-0 0-98
Total fretrospectivc'lv
stratified fol se(x) 17t) 94 1(0134 0) 91
58
CY (i.\.)
N ( E ()/E Comments
95 (64 55 1 15 Al & P apparenitly
better
79 41 40() 1 02 No apparent
(lifferenee
174 10()51 95'6 110
Males
I' rIa1e'S
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TABLE VI.-First-line treatment in the non-azotaemic stratum ofpatients: good and poor
prognosispatients separately (% patients in thepoor-prognosis category is small because
the azotaemic stratum ofpatients is excluded)
M & P (P.O.)
Prognosis N 0 E O/E
Good 52 17 19-6 0-76
Intermediate 114 64 71-5 0-89
Poor 13 13 8-9 1-46
Total (retrospectively
stratified for initial
prognosis) I179 94 1000 0-94
CY (i.v.)
N- ----/
N 0 E 0/E
49
110
15
18
74
13
15-4 1P17
66-5 1-11 f
17-1 0-76
Comments
M & P apparently
better
CY apparently
better
174 105 99*0 1-06
individual patient cannot be determined in
this way. This is not surprising in view of
the number of possible comparisons, but,
no consistent patterns emerged, and there
is insufficient evidence to infer that
different subgroups would fare better on
different treatments. Treatment differ-
ences are shown separately for each sex in
Table V, and for separate prognostic
groups in Table VI.
Sub-trial No. 2: First-line cytotoxic treat-
mentfor azotaemicpatients
Among the 132 patients randomized
between i.v. CY and the more toxic 4-drug
combination, there was again no material
difference in the distribution of any
feature of interest in the two treatment
groups (data not shown) nor was there any
suggestion of a difference in survival
(Fig. 3 and Table VII).
l",
FiG. 3.-Treatment comparisons for the
azotaemic stratum of patients (BUC > 10
mM). X2 =0 13 P =0.72.
TABLE VII.-Deaths in the azotaemic
stratum ofpatients in relation tofirst-line
treatment
First-line
treatment
CY
4-drug
Total
N
71
61
132
0
62
49
111
E O/E
60-1 1-03
50 9 0-96
111.0 (X2=0-13,
P=0.72)
These limited data do not, of course,
disprove the hypothesis that 10-20% of
azotaemic patients might benefit from an
aggressive cytotoxic attack, but they give
little or no encouragement to it, and unless
other evidence is forthcoming, a single
agent, if only because it is likely to be less
toxic, appears to remain the treatment of
choice, particularly for patients such as
the group of 48 with severe azotaemia
(BUC > 16 mM) among whom the single
agent actually appeared to be somewhat
better (Table VIII).
Sub-trial No. 3: Comparison between main-
tenance with a cycle-active combination and
no maintenance
Sub-trial No. 3 is at an earlier stage than
sub-trial No. 1, as 171/297 randomized
patients remained alive on 1 January
1980, compared with 44% of the patients
in Sub-trial No. 1. At present there is a
small non-significant (P=0.13) overall
difference in favour of continued main-
tenance (Fig. 4 and Table IX). In good-
prognosis patients, a number of deaths
occurred in the maintenance group soon
after beginning this treatment. However,
further follow-up has had a balancing
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TABLE VIII.-First-line treatmentintheazotaemicstratumofpatients: treatmentdifferences
separately among those with moderate and severe azotaemia
CY
r-
BUC N 0 E O/E
10-16mM 44 37 31-97 1-15
> 16 mM 27 25 31-40 0-80
Total (retrospectively
stratified for BUC) 71 62 63-37 0-98
4-Drug
N
40
21
0
28
21
E O/E
33-03 0-84
14-60 1-44
61 49 47-63 1-03
effect, and there
between the two
Table X). Further
I ; :k
1':d.
X , , 4,: '
FIG. 4.-Survival cu:
ized either to rece
or stop cytotoxi(
x2=2-27,P= 013.
TABLE IX.-Mort
tenan
Main-
tenance N
None until
needed 143
Cycle-active
agents 154
Total 297
is now little difference of patients is needed, as only 27 deaths
strategies (Fig. 5a and have occurred. Intermediate-prognosis
rfollow-up of this group patients fared slightly better on main-
tenance therapy. However, there was an
aJ apparent difference in poor-prognosis
patients. Ofthe 30 poor-prognosis patients
\,. who lived one year and were available for A
T randomization, those who received main-
e- <4$W tenance therapy did better (Fig. 5c). The
result was statistically significant (nominal
P =0-002) and also of important absolute
magnitude (relative death rate 1-94 stop,
0-59 continue). However, when allowance
- -- 9is made for the number of subgroups
r'{; is-^ X examined the true significance level will
i be less extreme than this. An overall com-
parison stratifying for prognostic groups
yields a marginally significant advantage
rves for patients random to maintenance therapy (x2 =432, P=
ive maintenance therapy 0X04). However, most of this effect is due
c therapy until needed. to poor-prognosis patients who may not
have reached "plateau" and were still
ality in relation to main- responding to the first-line treatment. The
ce treatment randomization for stop/continue was made after 1 year, whether or not the patients
O E O/E who were still alive were still responding
to treatment as shown bythe trend intheir
68 59-56 1-14 paraprotein concentrations. A recent re-
58 66-44 0-87 port from Durie et al. (1980) may help in
126 126.00 (X2=227, determining which patients might benefit
P=013) from maintenance therapy.
TABLE X.-Mortality in relation to maintenance treatment among patients classified
(a year or more previously) as good, intermediate or poorprognosis
Maintenance
r- -5
Not unless needed
Prognosis N 0 E O/E N
1 46 13 13-56 0-96 46 'mediate 83 42 36-35 1-16 92
14 13 6-72 1-94 16
Total (retrospectively
stratified for initial
prognosis) I
Cycle-active
O E O/E
14 13-47 1-04
35 40-65 0-86
9 15-28 0-59
143 68 56-60 1-20
Good
Inter
Poor
829
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FIG. 5. Survival curves for stopping or con-
tinuing maintenance therapy for the 3
prognostic groups separately: (a) Good
prognosis. x2=0-04, P=0-84. (b) Inter-
mediate prognosis. x2=0-04, P=0 20.
(c) Poor prognosis. X2=9_19, P=0-002.
Stratifie(d overall analysis x2 = 4-32, P =
0-04.
DISCUSSION
With the possible exception of the need
for continued treatment beyond 1 year
(especially for poor-prognosis patients) no
clear differences between treatments have
emerged in this, as in the other MRC
myelomatosis trials. Because the treat-
ments are about equivalent in their effects
on survival, the choice depends on con-
venience, acceptance, and toxicity, rather
than on efficacy; for most ptaients inter-
mittent melphalan and prednisone seems
better. For patients who receive inade-
quate treatment because of myelotoxicity
due to melphalan, the less myelotoxic
cyclophosphamide is likely to be more
effective. Whether some other class of
cytotoxic agent (e.g. vincristine) should be
added to the basic alkylating agent is one
of the questions asked in the 4th MRC
trial, which has just begun. The 4th trial
will also provide further data on the
advantages of continued maintenance
cytotoxic therapy for patients whose
disease has stabilized in a "plateau" phase.
We thank the many colleaguc wlho have referroed
patients to the trial. The work of Jack Cuzick was
supported by a Research Fellowship awarded by the
International Agency for Cancer Researcl.
REFERENCES
AZAM, L. & DELAMORE, I. W. (1974) Combination
therapy for myelomatosis. Br. Med. J., iv, 560.
DURIE, B. G. M., RUSSELL, D. H. & SALMON, S. E.
(1980) Reappraisal of plateau phase in myeloma.
Lancet, ii, 65.
MEDICAL RESEARCH COUNCIL (1971) Myelomatosis:
Comparison of melphalan and cyclophosplhamide
therapy. Br. Med. J., i, 640.
AMEDICAL RESEARCH COUNCIL (1973) Report on the
first mvelomatosis trial, Part, I. Br. J. Haematol.,
24, 123.
MEDICAL RESEARCH COUNCIL (1980) Prognostic
features in the third MRC myelomatosis trial.
Br. J. Cancer, 42, 831.
PETO, R., PIKE, M. C., ARMITAGE, P. & 7 otlhers
(1976; 1977) Design and analvsis of randomized
clinical trials whiclh require prolonged observation
of each patient. Br. J. Cancer, 34, 585, 35, 1.
SALMON, S. E. (1975) Expansion of the growth
fraction in multiple myeloma with alkylating
agents. Blood, 45, 119.
830
A3 P,W,g Wz. 7'.
155